Its marketed as a low-effort, natural alternative to GLP-1 medications
New members starting a GLP-1 for weight loss must have a BMI of 40 or higher to qualify for coverage
GLP-1 lawsuits involve allegations that certain medications used for diabetes treatment and weight management caused serious medical conditions affecting the digestive system, gallbladder, pancreas, and optic nerve
Most doctors say not to use semaglutide while pregnant unless the good outweighs the bad, mainly because it may affect how the baby grows
Private providers typically require similar BMI thresholds but may have different approaches to eligibility criteria
The cases name Novo Nordisk, the manufacturer of Ozempic and Wegovy, and assert that the company knew or should have known about a connection between semaglutide and optic nerve damage based on clinical data, post marketing reports, and emerging medical research